TODAY at 2 pm EST: Explore novel glioma treatments, innovations in docetaxel delivery, and critical updates on prostate cancer therapy in our International Monthly Webinar. Expand your knowledge with these experts: - Andrea Gómez, PharmD, BCACP, will share clinical pearls from NCODA’s PQI Vorasidenib resource for diffuse glioma treatment. - Shraddha Kansagra, PharmD, BCOP, discusses key takeaways on darolutamide and the ARASENS trial. - Syed Zia Khan, Pharm.D., BCSCP, breaks down polysorbate-80-free formulations, multi-dose vial advances, and reimbursement strategies for Docivyx. NCODA members can access all webinars at the link below. Please reach out to?[email protected]?if further assistance is needed. https://lnkd.in/eyeGJdGW?
关于我们
NCODA is a grassroots, not-for-profit organization, founded to strengthen community oncology practices with dispensing services. NCODA is addressing the growing need for dispensing cancer clinics to improve operations at the pharmacy level in order to deliver quality and sustainable value to all stakeholders involved in the care of cancer patients’ receiving oral and IV therapy. NCODA brings value to practices through adoption of Quality Standards, sharing of best practices and improving financial viability. Through NCODA, dispensing practices will be in a position to further demonstrate their high quality and patient-centered focus. With NCODA’s value proposition, community oncology practices will be able to convey to all stakeholders why it is vitally important for a patient’s treatment to remain with their oncologist from first fill through refills. This value proposition creates a win-win solution for all stakeholders involved in oral chemotherapy including patients, employers, payers, practices, pharmaceutical companies, advocacy groups, professional organizations, PBMs, GPOs, foundations, legislators, and state boards of pharmacy. NCODA’s membership is comprised of like-minded community cancer centers from across the country and is rapidly spreading to additional states who operate a dispensing platform. NCODA is rapidly growing and has expanded to represent over 3,000 prescribers nationally. NCODA will always be independent for its stakeholders, as it formulates a collaborative drug therapy management model which is so vitally important to the increasing number of patients prescribed oral chemotherapy and the providers involved in their care.
- 网站
-
https://www.ncoda.org
NCODA的外部链接
- 所属行业
- 医院和医疗保健
- 规模
- 11-50 人
- 总部
- Cazenovia，NY
- 类型
- 非营利机构
- 创立
- 2015
- 领域
- Physician Office Dispensing、Oral Oncolytics、Quality Standards和Practice Efficiency
地点
-
主要
获取路线
PO Box 468
US，NY，Cazenovia，13035
NCODA员工
动态
-
Tomorrow at 2 PM EST, join us for an International Monthly Webinar packed with expert insights on glioma, prostate cancer, and innovations in docetaxel delivery. Here’s what you’ll learn from the experts: ?? Andrea Gómez, PharmD, BCACP – Clinical pearls on diffuse glioma treatment from NCODA’s PQI Vorasidenib resource. ?? Shraddha Kansagra, PharmD, BCOP – Insights on darolutamide and the ARASENS trial. ??Syed Zia Khan, Pharm.D., BCSCP – Advances in Docivyx formulations, multi-dose vials, and reimbursement strategies. Learn more:?https://lnkd.in/eyeGJdGW?
-
-
The FDA has approved updated drug labeling for fludarabine phosphate as part of Project Renewal, an initiative to modernize and enhance prescribing information for older oncology drugs. This update ensures that the prescribing information is scientifically current, clinically relevant, and increases transparency to the FDA review process by enlisting external oncology experts to evaluate evidence. ? Fludarabine Phosphate Injection is now approved for the following new and revised indications: As a component of a combination regimen for the treatment of adults with B-cell chronic lymphocytic leukemia (CLL); and For the treatment of adults with B-cell CLL who have not responded to or whose disease has progressed during treatment with at least one alkylating-agent containing regimen. ? Updates include dosage modifications for renal impairment, safety warnings (like neurotoxicity and bone marrow suppression), and ensuring the label complies with contemporary formatting standards such as the Physician Labeling Rule (PLR) and the Pregnancy and Lactation Labeling Rule (PLLR). ? This is another milestone in Project Renewal's mission to provide healthcare professionals with the most reliable information for treating cancer patients, reinforcing the FDA’s commitment to patient safety and informed care decisions. Learn more about this initiative and its benefits: https://lnkd.in/gCcpTev7 #passionforpatients
-
Applications are now open for NCODA's Medically Integrated Oncology Pharmacy Residency Program! This unique opportunity is designed for recent pharmacy graduates and current pharmacists looking to specialize in oncology. Through this one-year program, residents will gain comprehensive training, mentorship from leading oncology clinicians, and valuable career advancement opportunities. Learn more and submit your application using the link below. The submission deadline is January 31, 2025. https://lnkd.in/geaVnywX
-
-
Chemotherapy-induced nausea and vomiting (CINV) are some of the most challenging side effects cancer patients face, affecting their daily lives and treatment adherence.?Effective management requires more than just medication; it requires clear, compassionate communication and precise symptom tracking. The CINV Assessment Tool was designed to help the multidisciplinary care team do just that. By engaging in meaningful conversations with patients while streamlining symptom tracking, this tool makes it easier to offer personalized care and improve outcomes. It’s a simple yet powerful way to ensure patients feel supported throughout their treatment journey. Learn more & access this resource:?https://lnkd.in/eXCaE_VZ
-
-
For patients with isocitrate dehydrogenase mutant low-grade gliomas, vorasidenib is making a difference in managing this complex condition. However, appropriate patient selection and diligent monitoring are key to achieving optimal outcomes. NCODA’s recently published PQI on vorasidenib provides valuable insights into identifying the right candidates for vorasidenib, as well as clinical pearls for monitoring and follow-up to ensure the treatment is as effective as possible. Explore this PQI here:?https://lnkd.in/eSDNUT27
-
A Shout-out to Donnell Hale, MBA, BSN, RN, OCN, for sharing insightful research during the digital poster session at the NCODA Fall Summit on developing a nurse navigation program for oral anti-cancer medications. This kind of innovation within our community drives real change in #oncology care! ? Explore more of the inspiring work shared at the Summit here: https://lnkd.in/gGe7mu2V
?? Late post, but still just as proud! ?? I want to take a moment to recognize my incredible colleague, Donnell Hale, for her informative and impactful poster presentation at NCODA this past October. Her dedication and expertise shined through, and her contributions are a testament to her commitment to advancing oncology care. Donnell, I couldn’t be prouder to work alongside you. Even though this shout-out is delayed, it doesn’t diminish the admiration I have for your accomplishments. Well done! ?? #Teamwork #OncologyCare #NCODA #ProudColleague
-
-
FDA approves revumenib for relapsed or refractory acute leukemia with a KMT2A translocation. https://lnkd.in/gZMaJMwg #passionforpatients #AML
FDA approves revumenib for relapsed or refractory acute leukemia
fda.gov
-
Accessing effective treatment shouldn’t be complicated. TODAY at 2 pm EST, discover how darolutamide fits into #prostatecancer care and explore Bayer's resources to make patient support easier. Led by Bayer's Elizabeth Bautista, Tim Clark, and Michael Furman, gain key insights on financial assistance, prescribing tools, and patient programs. Join here:?https://lnkd.in/eyeGJdGW
-
-
November is #PancreaticCancer Awareness Month, a time to highlight the importance of informed care for patients undergoing treatment and their caregivers. FOLFIRINOX, a common treatment for pancreatic cancer, is known for its effectiveness in improving patient outcomes. However, it can cause side effects like fatigue, nausea, and neutropenia. This Intravenous Chemotherapy patient education sheet (IVE) on FOLFIRINOX offers key details, including treatment schedules, drug interactions, and tips for managing side effects like hydration and nutrition. Sharing this resource helps empower patients and caregivers to confidently navigate treatment. Explore this resource and share it with your patients:?https://lnkd.in/ebF4JW3r